Association between High Triglyceride-to-HDL Cholesterol Ratio and Nephrotic Proteinuria in CKD Patients
Keywords:
triglyceride, HDL cholesterol, nephrotic proteinuria, chronic kidney diseasesAbstract
Background and Objective: Chronic kidney disease(CKD) patients face an increased risk of cardiovascular disease. High triglyceride-to-HDL cholesterol ratio(TG-HDL ratio) and nephrotic proteinuria constitute risk predictors of CKD progression and cardiovascular disease. However, the association between this ratio and proteinuria in CKD patients remains unknown. The aim of this study was to investigate relationship between high TG-HDL ratio and proteinuria in CKD patients.
Methodology : The case control analytic study included patients who were examined at the Chronic Kidney Disease Clinic at Thasala hospital between February to March 2023. Participants were divided into two categories according to nephrotic proteinuria. The main outcome measure was to determine relationship between high TG-HDL ratio and nephrotic proteinuria. Multiple variate analysis was performed to reveal relationship between nephrotic proteinuria and other factors.
Results : This study included 167 patients and median age was 72 years. The number of CKD patients is divided into three stages: stage 3 with 74 cases (44.3%), stage 4 with 61 cases (36.5%), and stage 5 with 32 cases (19.2%). There were 31 patients(21.6%) with nephrotic proteinuria. High TG-HDL ratio were significantly associated to nephrotic proteinuria(ORadj=1.45, 95% CI=1.2–1.77, p=0.001). Factors which were associated with nephrotic proteinuria significantly were glomerular filtration rate(ORadj =0.91, 95% CI=0.86–0.97, p<0.001), fasting blood sugar (ORadj =1.02, 95% CI=1.01–1.04, p=0.02) and age(ORadj =1.07, 95% CI=1.01–1.13, p=0.01). Using 3.92 as a cut-off value, a TG-HDL ratio was a useful marker (p<0.001) for nephrotic proteinuria.
Conclusion : This study demonstrated the association between high TG-HDL ratio and nephrotic proteinuria in CKD patients. Other factors associated with nephrotic proteinuria were glomerular filtration rate, fasting blood sugar and age.
References
Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJL, Mann JF, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 2013;382(9889):339-52. doi.org/10.1016/S0140-6736(13)60595-4
Li G, Wu Hk, Wu XW, Cao Z, Tu YC, Ma Y, et al. Small dense low density lipoprotein-cholesterol and cholesterol ratios to predict arterial stiffness progression in normotensive subjects over a 5-year period. Lipids Health Dis 2018;17(1):1-10. doi.org/10.1186/s12944-018-0671-2
Ouchi G, Komiya I, Taira S, Wakugami T, Ohya Y. Triglyceride/low-density-lipoprotein cholesterol ratio is the most valuable predictor for increased small, dense LDL in type 2 diabetes patients. Lipids Health Dis 2022;21(1):1-12. doi.org/10.1186/s12944-021-01612-8
Moriyama K, Takahashi E. Non-HDL cholesterol is a more superior predictor of small-dense LDL cholesterol than LDL cholesterol in Japanese subjects with TG levels< 400 mg/dL. J Atheroscler Thromb 2016;23(9):1126-37. doi.org/10.5551/jat.33985
Nerpin E, Ingelsson E, Risérus U, Sundström J, Larsson A, Jobs E, et al. The combined contribution of albuminuria and glomerular filtration rate to the prediction of cardiovascular mortality in elderly men. Nephrol Dial Transplant 2011;26(9):2820-7. doi.org/10.1093/ndt/gfq848
Matsushita K, Coresh J, Sang Y, Chalmers J, Fox C, Guallar E, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol 2015;3(7):514-25. doi.org/10.1016/S2213-8587(15)00040-6
Ying T, Clayton P, Naresh C, Chadban S. Predictive value of spot versus 24-hour measures of proteinuria for death, end-stage kidney disease or chronic kidney disease progression. BMC Nephrol 2018;19(1):55. doi.org/10.1186/s12882-018-0853-1
Russo LM, Comper WD, Osicka TM. Mechanism of albuminuria associated with cardiovascular disease and kidney disease. Kidney Int Suppl 2004;(92):S67-8. doi.org/10.1111/j.1523-1755.2004.09218.x
Sibley SD, Hokanson JE, Steffes MW, Purnell JQ, Marcovina SM, Cleary PA, et al. Increased small dense LDL and intermediate-density lipoprotein with albuminuria in type 1 diabetes. Diabetes care 1999;22(7):1165-70. doi.org/10.2337/diacare.22.7.1165
Lee IT, Wang CY, Huang CN, Fu CC, Sheu WHH. High triglyceride-to-HDL cholesterol ratio associated with albuminuria in type 2 diabetic subjects. J Diabetes Complication 2013;27(3):243-7. doi.org/10.1016/j.jdiacomp.2012.11.004
Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int 2000;58(1):293-301. doi.org/10.1046/j.1523-1755.2000.00165.x
Nguyen HH, Tran HH, Nguyen LT, Nguyen T, Nguyen NA, Vi MT, et al. TG/HDL-C ratio is a risk factor associated with CKD: use in assessing the risk of progression of CKD. Pathophysiology 2022;29(3):374-82. doi.org/10.3390/pathophysiology29030029
Iwai T, Miyazaki M, Yamada G, Nakayama M, Yamamoto T, Satoh M, et al. Diabetes mellitus as a cause or comorbidity of chronic kidney disease and its outcomes: the Gonryo study. Clin Exp Nephrol 2018;22(2):328-36. doi.org/10.1007/s10157-017-1451-4
Sun K, Lin D, Li F, Huang C, Qi Y, Xue S, et al. Discordant associations of lipid parameters with albuminuria and chronic kidney disease: a population-based study. Lipids Health Dis 2015;14:152. doi.org/10.1186/s12944-015-0153-8
Hallan SI, Matsushita K, Sang Y, Mahmoodi BK, Black C, Ishani A, et al. Age and association of kidney measures with mortality and end-stage renal disease. J Am Med Assoc 2012;308(22):2349-60. doi.org/10.1001/jama.2012.16817
Chen SC, Hung CC, Kuo MC, Lee JJ, Chiu YW, Chang JM, et al. Association of dyslipidemia with renal outcomes in chronic kidney disease. PLoS One 2013;8(2):e55643. doi.org/10.1371/journal.pone.0055643
Ho CI, Chen JY, Chen SY, Tsai YW, Weng YM, Tsao YC, et al. Relationship between TG/HDL-C ratio and metabolic syndrome risk factors with chronic kidney disease in healthy adult population. Clin Nutr 2015;34(5):874-80. doi.org/10.1016/j.clnu.2014.09.007
Bommer J. Prevalence and socio‐economic aspects of chronic kidney disease. Nephrol Dial Transplant 2002;17 (Suppl 11):8-12. doi.org/10.1093/ndt/17.suppl_11.8
Molnar MZ, Kalantar-Zadeh K, Lott EH, Lu JL, Malakauskas SM, Ma JZ, et al. Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker use, and mortality in patients with chronic kidney disease. J Am Coll Cardiol 2014;63(7):650-8. doi.org/10.1016/j.jacc.2013.10.050
Bolton CH, Downs LG, Victory JG, Dwight JF, Tomson CR, Mackness MI, et al. Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and pro‐inflammatory cytokines. Nephrol Dial Transplant 2001;16(6):1189-97. doi.org/10.1093/ndt/16.6.1189
Magil AB. Interstitial foam cells and oxidized lipoprotein in human glomerular disease. Mod Pathol 1999;12(1):33-40.
Trevisan R, Dodesini AR, Lepore G. Lipids and renal disease. J Am Soc Nephro 2006;17 (4 Suppl 2):S145-S7. doi.org/10.1681/ASN.2005121320
Hsieh MH, Yang JF, Lin WY, Chien HH, Kuo MC, Chang NC, et al. Fasting sugar, blood pressure, and uric acid are factors related to positive proteinuria and an impaired eGFR. J Chin Med Assoc 2017;80(12):782-9. doi.org/10.1016/j.jcma.2016.11.011
Ekinci EI, Jerums G, Skene A, Crammer P, Power D, Cheong KY, et al. Renal structure in normoalbuminuric and albuminuric patients with type 2 diabetes and impaired renal function. Diabetes care 2013;36(11):3620-6. doi.org/10.2337/dc12-2572
Obi Y, Kimura T, Nagasawa Y, Yamamoto R, Yasuda K, Sasaki K, et al. Impact of age and overt proteinuria on outcomes of stage 3 to 5 chronic kidney disease in a referred cohort. Clin J Am Soc Nephrol 2010;5(9):1558-65. doi.org/10.2215/CJN.08061109
Fuiano G, Sund S, Mazza G, Rosa M, Caglioti A, Gallo G, et al. Renal hemodynamic response to maximal vasodilating stimulus in healthy older subjects. Kidney Int 2001;59(3):1052-8. doi.org/10.1046/j.1523-1755.2001.0590031052.x
Ansquer J-C, Foucher C, Rattier S, Taskinen M-R, Steiner G, Investigators D. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 2005;45(3):485-93. doi.org/10.1053/j.ajkd.2004.11.004
Lane C, Brown M, Dunsmuir W, Kelly J, Mangos G. Can spot urine protein/creatinine ratio replace 24 h urine protein in usual clinical nephrology? Nephrol 2006;11(3):245-9. doi.org/10.1111/j.1440-1797.2006.00564.x
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Srinagarind Medical Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
